{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:20:04Z","timestamp":1791894004516,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,3,20]],"date-time":"2012-03-20T00:00:00Z","timestamp":1332201600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"DOI":"10.1038\/tp.2012.15","type":"journal-article","created":{"date-parts":[[2012,3,13]],"date-time":"2012-03-13T16:04:08Z","timestamp":1331654648000},"page":"e94-e94","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":911,"title":["Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia"],"prefix":"10.1038","volume":"2","author":[{"given":"F M","family":"Leweke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Piomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Pahlisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Muhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C W","family":"Gerth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Hoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Klosterk\u00f6tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Koethe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,3,20]]},"reference":[{"key":"BFtp201215_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1586\/14737175.9.1.47","volume":"9","author":"DP Rogers","year":"2009","unstructured":"Rogers DP, Goldsmith CA . Treatment of schizophrenia in the 21st century: beyond the neurotransmitter hypothesis. Expert Rev Neurother 2009; 9: 47\u201354.","journal-title":"Expert Rev Neurother"},{"key":"BFtp201215_CR2","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nrn1247","volume":"4","author":"D Piomelli","year":"2003","unstructured":"Piomelli D . The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003; 4: 873\u2013884.","journal-title":"Nat Rev Neurosci"},{"key":"BFtp201215_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s002130050884","volume":"142","author":"FM Leweke","year":"1999","unstructured":"Leweke FM, Schneider U, Thies M, M\u00fcnte TF, Emrich HM . Effects of synthetic \u03949-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacology 1999; 142: 230\u2013235.","journal-title":"Psychopharmacology"},{"key":"BFtp201215_CR4","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/sj.npp.1300496","volume":"29","author":"CD D\u2019Souza","year":"2004","unstructured":"D\u2019Souza CD, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu Y-T et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004; 29: 1558\u20131572.","journal-title":"Neuropsychopharmacology"},{"key":"BFtp201215_CR5","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/npp.2010.222","volume":"36","author":"PD Morrison","year":"2011","unstructured":"Morrison PD, Nottage J, Stone JM, Bhattacharyya S, Tunstall N, Brenneisen R et al. Disruption of frontal theta coherence by Delta(9)-tetrahydrocannabinol is associated with positive psychotic symptoms. Neuropsychopharmacology 2011; 36: 827\u2013836.","journal-title":"Neuropsychopharmacology"},{"key":"BFtp201215_CR6","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.biopsych.2004.12.006","volume":"57","author":"DC D\u2019Souza","year":"2005","unstructured":"D\u2019Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005; 57: 594\u2013608.","journal-title":"Biol Psychiatry"},{"key":"BFtp201215_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1192\/bjp.bp.109.072249","volume":"196","author":"C Henquet","year":"2010","unstructured":"Henquet C, van Os J, Kuepper R, Delespaul P, Smits M, Campo JA et al. Psychosis reactivity to cannabis use in daily life: an experience sampling study. Br J Psychiatry 2010; 196: 447\u2013453.","journal-title":"Br J Psychiatry"},{"key":"BFtp201215_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/00008877-200006000-00008","volume":"11","author":"B Scatton","year":"2000","unstructured":"Scatton B, Sanger DJ . Pharmacological and molecular targets in the search for novel antipsychotics. Behav Pharmacol 2000; 11: 243\u2013256.","journal-title":"Behav Pharmacol"},{"key":"BFtp201215_CR9","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/archpsyc.65.7.772","volume":"65","author":"SM Eggan","year":"2008","unstructured":"Eggan SM, Hashimoto T, Lewis DA . Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry 2008; 65: 772\u2013784.","journal-title":"Arch Gen Psychiatry"},{"key":"BFtp201215_CR10","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","volume":"161","author":"HY Meltzer","year":"2004","unstructured":"Meltzer HY, Arvanitis L, Bauer D, Rein W . Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 2004; 161: 975\u2013984.","journal-title":"Am J Psychiatry"},{"key":"BFtp201215_CR11","unstructured":"Sanofi-Aventis. Efficacy and safety of AVE1625 as a co-treatment with antipsychotic therapy in schizophrenia (CONNECT). ClinicalTrials gov, May 11 2010; edn, vol. NCT00439634. US National Institute of Health, 2010."},{"key":"BFtp201215_CR12","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1097\/00001756-199906030-00008","volume":"10","author":"FM Leweke","year":"1999","unstructured":"Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D . Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999; 10: 1665\u20131669.","journal-title":"Neuroreport"},{"key":"BFtp201215_CR13","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","volume":"29","author":"A Giuffrida","year":"2004","unstructured":"Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004; 29: 2108\u20132114.","journal-title":"Neuropsychopharmacology"},{"key":"BFtp201215_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/MOL.0b013e32803dbdec","volume":"18","author":"V Di Marzo","year":"2007","unstructured":"Di Marzo V, Petrosino S . Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 2007; 18: 129\u2013140.","journal-title":"Curr Opin Lipidol"},{"key":"BFtp201215_CR15","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1523\/JNEUROSCI.20-09-03401.2000","volume":"20","author":"M Beltramo","year":"2000","unstructured":"Beltramo M, de Fonseca FR, Navarro M, Calignano A, Gorriti MA, Grammatikopoulos G et al. Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J Neurosci 2000; 20: 3401\u20133407.","journal-title":"J Neurosci"},{"key":"BFtp201215_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1017\/S146114570999023X","volume":"13","author":"A Seillier","year":"2010","unstructured":"Seillier A, Advani T, Cassano T, Hensler JG, Giuffrida A . Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. Int J Neuropsychopharmacol 2010; 13: 373\u2013386.","journal-title":"Int J Neuropsychopharmacol"},{"key":"BFtp201215_CR17","doi-asserted-by":"publisher","first-page":"PL1","DOI":"10.1016\/S0024-3205(98)00238-0","volume":"63","author":"F Petitet","year":"1998","unstructured":"Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq M-C . Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta-9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 1998; 63: PL1\u2013PL6.","journal-title":"Life Sci"},{"key":"BFtp201215_CR18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","volume":"150","author":"A Thomas","year":"2007","unstructured":"Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG . Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 2007; 150: 613\u2013623.","journal-title":"Br J Pharmacol"},{"key":"BFtp201215_CR19","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","volume":"134","author":"T Bisogno","year":"2001","unstructured":"Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001; 134: 845\u2013852.","journal-title":"Br J Pharmacol"},{"key":"BFtp201215_CR20","first-page":"485","volume":"56","author":"AW Zuardi","year":"1995","unstructured":"Zuardi AW, Morais SL, Guimar\u00e3es FS, Mechoulam R . Antipsychotic effect of cannabidiol. J Clin Psychiatry 1995; 56: 485\u2013486.","journal-title":"J Clin Psychiatry"},{"key":"BFtp201215_CR21","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1177\/0269881106060967","volume":"20","author":"AW Zuardi","year":"2006","unstructured":"Zuardi AW, Hallak JE, Dursun SM, Morais SL, Faria Sanches R, Musty RE et al. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol 2006; 20: 683\u2013686.","journal-title":"J Psychopharmacol"},{"key":"BFtp201215_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0091-3057(00)00201-X","volume":"66","author":"FM Leweke","year":"2000","unstructured":"Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM . Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacol Biochem Behav 2000; 66: 175\u2013181.","journal-title":"Pharmacol Biochem Behav"},{"key":"BFtp201215_CR23","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/npp.2009.184","volume":"35","author":"S Bhattacharyya","year":"2010","unstructured":"Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010; 35: 764\u2013774.","journal-title":"Neuropsychopharmacology"},{"key":"BFtp201215_CR24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ab.2006.11.027","volume":"361","author":"D Schreiber","year":"2007","unstructured":"Schreiber D, Harlfinger S, Nolden BM, Gerth CW, Sch\u00f6mig E, Klosterk\u00f6tter J et al. Determination of anandamide and other fatty acylethanolamides in human serum by electrospray tandem mass spectrometry. Anal Biochem 2007; 361: 162\u2013168.","journal-title":"Anal Biochem"},{"key":"BFtp201215_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1006\/abio.2000.4509","volume":"280","author":"A Giuffrida","year":"2000","unstructured":"Giuffrida A, Rodriguez de Fonseca F, Piomelli D . Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry. Anal Biochem 2000; 280: 87\u201393.","journal-title":"Anal Biochem"},{"key":"BFtp201215_CR26","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1176\/ajp.156.4.610","volume":"156","author":"JM Danion","year":"1999","unstructured":"Danion JM, Rein W, Fleurot O . Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry 1999; 156: 610\u2013616.","journal-title":"Am J Psychiatry"},{"key":"BFtp201215_CR27","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1177\/009286150103500421","volume":"35","author":"D Hauschke","year":"2001","unstructured":"Hauschke D, Kieser M . Multiple testing to establish noninferiority of k treatments with a reference based on the ratio of two means. Drug Inf J 2001; 35: 1247\u20131251.","journal-title":"Drug Inf J"},{"key":"BFtp201215_CR28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1600-0447.2005.00659.x","volume":"113","author":"J van Os","year":"2006","unstructured":"van Os J, Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L et al. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 2006; 113: 91\u201395.","journal-title":"Acta Psychiatr Scand"},{"key":"BFtp201215_CR29","unstructured":"Committee for proprietary medicinal products (CPMP). Note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia. February 26 1998; CPMP\/EWP\/559\/95, The European Agency for the Evaluation of Medicinal Products, London, 1998."},{"key":"BFtp201215_CR30","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1176\/appi.ajp.159.2.180","volume":"159","author":"S Leucht","year":"2002","unstructured":"Leucht S, Pitschel-Walz G, Engel RR, Kissling W . Amisulpride, an unusual \u2018atypical\u2019 antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002; 159: 180\u2013190.","journal-title":"Am J Psychiatry"},{"key":"BFtp201215_CR31","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.tips.2009.07.006","volume":"30","author":"AA Izzo","year":"2009","unstructured":"Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R . Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009; 30: 515\u2013527.","journal-title":"Trends Pharmacol Sci"},{"key":"BFtp201215_CR32","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1192\/bjp.bp.108.053843","volume":"194","author":"D Koethe","year":"2009","unstructured":"Koethe D, Giuffrida A, Schreiber D, Hellmich M, Schultze-Lutter F, Ruhrmann S et al. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry 2009; 194: 371\u2013372.","journal-title":"Br J Psychiatry"},{"key":"BFtp201215_CR33","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1177\/0269881107083816","volume":"22","author":"S Potvin","year":"2008","unstructured":"Potvin S, Kouassi E, Lipp O, Bouchard RH, Roy MA, Demers MF et al. Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. J Psychopharmacol 2008; 22: 262\u2013269.","journal-title":"J Psychopharmacol"},{"key":"BFtp201215_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1476-511X-2-5","volume":"2","author":"N De Marchi","year":"2003","unstructured":"De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V . Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 2003; 2: 5\u201313.","journal-title":"Lipids Health Dis"},{"key":"BFtp201215_CR35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archgenpsychiatry.2009.206","volume":"67","author":"S Ruhrmann","year":"2010","unstructured":"Ruhrmann S, Schultze-Lutter F, Salokangas RK, Heinimaa M, Linszen D, Dingemans P et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry 2010; 67: 241\u2013251.","journal-title":"Arch Gen Psychiatry"},{"key":"BFtp201215_CR36","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","volume":"30","author":"E Russo","year":"2005","unstructured":"Russo E, Burnett A, Hall B, Parker K . Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 2005; 30: 1037\u20131043.","journal-title":"Neurochem Res"},{"key":"BFtp201215_CR37","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","volume":"152","author":"E Ryberg","year":"2007","unstructured":"Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152: 1092\u20131101.","journal-title":"Br J Pharmacol"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/tp201215.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/tp201215","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tp201215.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T21:43:42Z","timestamp":1672955022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tp201215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,20]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,3]]}},"alternative-id":["BFtp201215"],"URL":"https:\/\/doi.org\/10.1038\/tp.2012.15","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,20]]},"assertion":[{"value":"13 October 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}